Claims for Patent: 8,273,569

Summary for Patent: 8,273,569

Title:	Preparation of human embryonic stem cells
Abstract:	A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (-); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.
Inventor(s):	Thomson; James A. (Madison, WI)
Assignee:	Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:	12/822,004
Patent Claims:	1. A preparation of pluripotent human embryonic stem cells comprising cells that (i) proliferate in vitro for over one year, (ii) maintain a karyotype in which the chromosomes are euploid through prolonged culture, (iii) maintain the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues, (iv) are inhibited from differentiation when cultured on a fibroblast feeder layer, and (v) are negative for the SSEA-1 cell surface marker and positive for SSEA-4 cell surface marker. 2. The preparation of claim 1, wherein the stem cells will spontaneously differentiate to trophoblasts that produce chorionic gonadotropin when cultured beyond confluence. 3. The preparation of pluripotent human embryonic stem cells as claimed in claim 1 wherein the cells express alkaline phosphatase activity. 4. The preparation of claim 3, wherein the cells are positive for the TRA-1-60, and TRA-1-81 markers. 5. The preparation of claim 2, wherein the cells will differentiate to trophoblasts that produce chorionic gonadotropin when cultured for two weeks beyond confluence. 6. The preparation of claim 3, wherein the cells remain euploid for more than one year of continuous culture. 7. The preparation of claim 3, wherein the cells differentiate into cells derived from mesoderm, endoderm and ectoderm germ layers when the cells are injected into a SCID mouse.

Details for Patent 8,273,569

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2030-06-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2030-06-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2030-06-23